Immunopotentiators NNS I-NP I-M
activate VBP I-VP I-P
innate JJ I-NP I-P
immunity NN I-NP I-P
directly RB O O
(for JJ I-NP O
example, NN I-NP O
cytokines) NN I-NP O
or CC O O
through IN I-PP O
pattern-recognition JJ I-NP I-P
receptors NNS I-NP I-P
(PRRs, VBP I-VP O
such JJ I-NP O
as IN I-PP O
those DT I-NP O
for IN I-PP O
bacterial JJ I-NP O
components). NN I-NP O

The DT I-NP O
Toll-like JJ I-NP I-P
receptors NNS I-NP I-P
(TLRs) EX B-NP O
are VBP I-VP O
a DT I-NP O
family NN I-NP O
of IN I-PP O
PRRs NNP I-NP I-P
that WDT B-NP O
are VBP I-VP O
an DT I-NP O
important JJ I-NP O
link NN I-NP O
between IN I-PP O
innate NN I-NP O
and CC O O
adaptive JJ I-NP O
immunity. NN I-NP O

Some DT I-NP O
studies NNS I-NP O
have VBP I-VP O
shown VBN I-VP O
that IN I-PP O
TLR NNP I-NP I-M
ligands NNS I-NP I-M
have VBP I-VP O
adjuvant JJ I-NP O
activity NN I-NP O
and CC O O
enhance VB I-VP O
antigen-specific JJ I-NP O
antibody NN I-NP O
and CC O O
cell-mediated JJ I-NP O
immune NN I-NP O
responses, NN I-NP O
especially RB O O
when WRB O O
they PRP I-NP O
are VBP I-VP O
combined VBN I-VP O
with IN I-PP O
delivery NN I-NP O
systems NNS I-NP O
that WDT B-NP O
promote VBP I-VP O
their PRP$ I-NP O
uptake NN I-NP O
and CC O O
delivery NN I-NP O
into IN I-PP O
antigen-presenting JJ I-NP I-M
cells NNS I-NP I-M
[22–24]. VBP I-VP O

For IN I-PP O
clinical JJ I-NP I-T
studies, NN I-NP I-T
TLR9 NNP I-NP I-M
is VBZ I-VP O
generally RB I-VP O
stimulated VBN I-VP I-P
with IN I-PP O
synthetic JJ I-NP I-M
oligodeoxynucleotides NNS I-NP I-M
containing VBG I-VP O
one CD I-NP O
or CC O O
more JJR O O
unmethylated JJ I-NP I-M
CpG NNP I-NP I-M
dinucleotides. NN I-NP I-M

In IN I-PP O
humans, NN I-NP O
CpG NNP I-NP I-M
has VBZ I-VP O
been VBN I-VP O
used VBN I-VP O
as IN I-PP O
an DT I-NP O
adjuvant NN I-NP I-M
for IN I-PP O
infectious JJ I-NP I-T
disease NN I-NP I-T
vaccination NN I-NP I-T
[25,26] NN I-NP O
and CC O O
in IN I-PP O
the DT I-NP O
development NN I-NP I-T
of IN I-PP I-T
cancer NN I-NP I-T
therapy NN I-NP I-T
[27]. NN I-NP O

In IN I-PP O
a DT I-NP O
mouse NN I-NP I-P
model, NN I-NP I-P
CpG NNP I-NP I-M
has VBZ I-VP O
also RB I-VP O
been VBN I-VP O
shown VBN I-VP O
to TO I-VP O
induce VB I-VP I-P
T NNP I-NP I-P
helper PRP B-NP I-P
1 CD I-NP I-P
(Th1) JJ I-NP O
immune NN I-NP O
responses, NN I-NP O
which WDT B-NP O
are VBP I-VP O
characterized VBN I-VP O
by IN I-PP O
the DT I-NP O
production NN I-NP I-P
of IN I-PP I-P
IFN-γ NNP I-NP I-P
and CC O I-P
the DT I-NP I-P
generation NN I-NP I-P
of IN I-PP I-P
IgG2a NNP I-NP I-P
[28,29]. NNP I-NP O

Moreover, NNP I-NP O
a DT I-NP O
previous JJ I-NP O
study NN I-NP O
had VBD I-VP O
demonstrated VBN I-VP O
that IN I-PP O
different JJ I-NP O
liposomes NNS I-NP I-M
with IN I-PP O
CpG NNP I-NP O
ODN NNP I-NP O
significantly RB O O
increased VBD I-VP O
Th1-biased JJ I-NP I-M
cytokines NNS I-NP I-M
and CC O O
augmented VBN I-VP I-P
cell NN I-NP I-P
mediated VBN I-NP I-P
immune JJ I-NP I-P
response NN I-NP I-P
[30]. NN I-NP O

